FML Taper When Starting Cyclosporine Drops
Use a short 2-4 week course of fluorometholone (FML) 0.1% when initiating cyclosporine 0.05%, then gradually taper by decreasing frequency over several weeks while continuing cyclosporine long-term. 1
Rationale for Corticosteroid Bridge Therapy
The 2024 AAO Dry Eye Preferred Practice Pattern explicitly supports short-term topical corticosteroid use to suppress acute ocular surface inflammation when starting anti-inflammatory therapy 1. This approach is clinically sound because:
- Cyclosporine has delayed onset of action (typically 6-12 weeks for full effect), while corticosteroids provide rapid symptom relief
- FML provides immediate anti-inflammatory control while cyclosporine's immunomodulatory effects develop
- Short-term steroid use (2-4 weeks) minimizes risks of IOP elevation and cataract formation 1
Specific Tapering Protocol
Initial Phase (Weeks 1-2)
- FML 0.1%: 2-4 times daily
- Cyclosporine 0.05%: Twice daily (start simultaneously)
- Artificial tears: Continue as needed
Taper Phase (Weeks 3-4)
- Gradually decrease FML frequency by one drop per week (e.g., QID → TID → BID → QD)
- Continue cyclosporine 0.05%: Twice daily without interruption
- Monitor for rebound inflammation during taper
Maintenance Phase (Week 5 onward)
- Discontinue FML completely after 4 weeks maximum
- Continue cyclosporine 0.05%: Twice daily for at least 6-12 months
- After 1 year, cyclosporine may be reduced to once daily in some patients 1
Evidence Supporting This Approach
Recent research directly validates this strategy. A 2025 study demonstrated that pretreatment with FML 0.1% before cyclosporine 0.1% significantly improved compliance (only 7.4% discontinuation rate versus 20% without pretreatment) 2. More importantly, another 2025 study showed that pretreatment with cyclosporine 0.05% augmented the anti-inflammatory effect of higher-dose cyclosporine, suggesting the bridge therapy concept is mechanistically sound 2.
The FDA label for FML explicitly states: "In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications" 3. This supports the gradual taper approach rather than abrupt discontinuation.
Critical Monitoring Points
During steroid taper, watch for:
- Rebound inflammation (increased redness, discomfort, staining) - may require slower taper
- IOP elevation - check at 2-4 weeks if using steroids longer than 2 weeks
- Cyclosporine burning sensation (occurs in 17% of patients) - reassure patient this typically improves with continued use 1
If inflammation flares during taper:
- Temporarily increase FML frequency back to previous level
- Extend taper duration by 1-2 weeks
- Ensure cyclosporine compliance is adequate
Common Pitfalls to Avoid
- Do not discontinue FML abruptly - this can cause rebound inflammation that undermines cyclosporine initiation
- Do not extend steroid use beyond 4-6 weeks without compelling reason - the guideline emphasizes "short periods of time (i.e., several weeks)" 1
- Do not stop cyclosporine prematurely - it requires 6-12 months of consistent use for disease-modifying effects 1
- Do not use preserved steroids if dosing >4 times daily - preservative toxicity can worsen ocular surface disease
Alternative Consideration
For patients with severe inflammation or steroid-responsive conditions, consider using loteprednol etabonate 0.5% instead of FML as it has lower IOP-raising potential, though the 2024 guideline notes that loteprednol 0.25% showed benefit over only 2-4 weeks 1.